Literature DB >> 15625281

Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells.

Alatangaole Damirin1, Hideaki Tomura, Mayumi Komachi, Masayuki Tobo, Koichi Sato, Chihiro Mogi, Hiromi Nochi, Koichi Tamoto, Fumikazu Okajima.   

Abstract

Sphingosine 1-phosphate (S1P) has been shown to exert a variety of biological responses through extracellular specific receptors or intracellular mechanisms. In the present study, we characterized a signaling pathway of S1P-induced cAMP accumulation in human coronary artery smooth muscle cells (CASMCs). S1P induced biphasic cAMP accumulation composed of a short-term and transient response (a peak at 2.5 min) and a late and sustained response ( approximately 4-6 h). The late phase of cAMP accumulation was parallel to the increment of cyclooxygenase-2 protein expression and was inhibited by N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methane sulfonamide (NS398), a cyclooxygenase-2-specific inhibitor. We were surprised to find that the cyclooxygenase-2 inhibitor also inhibited short-term cAMP accumulation even when cyclooxygenase-2 protein expression was not yet increased. More interestingly, the short-term cAMP accumulation was also completely inhibited by pertussis toxin, an inhibitor of G(i/o) proteins. JTE-013, a specific antagonist for S1P(2) receptors, inhibited the S1P-induced cAMP accumulation. Furthermore, small interfering RNAs targeted for S1P(2) receptors significantly inhibited the S1P-induced cAMP accumulation. The cAMP response was also inhibited by specific inhibitors for phospholipase C, extracellular signal-regulated kinase pathways, and cytosolic phospholipase A(2). S1P actually activated these enzyme activities and stimulated prostaglandin I(2) (PGI(2)) synthesis. Finally, exogenously applied arachidonic acid and PGI(2) induced cAMP accumulation to a similar extent as S1P. In conclusion, S1P induced cAMP accumulation through S1P receptors, including S1P(2) receptor and G(i/o) protein-mediated stimulation of intracellular signaling pathways involving cyclooxygenase-2-dependent PGI(2) synthesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15625281     DOI: 10.1124/mol.104.004317

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Metabolic tuning of inhibition regulates hippocampal neurogenesis in the adult brain.

Authors:  Xinxing Wang; Hanxiao Liu; Johannes Morstein; Alexander J E Novak; Dirk Trauner; Qiaojie Xiong; Yuguo Yu; Shaoyu Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-24       Impact factor: 11.205

Review 2.  Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine.

Authors:  Denise G Hemmings
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04       Impact factor: 3.000

3.  Inhibition of cyclooxygenase-2 modulates phenotypic switching of vascular smooth muscle cells during increased aortic blood flow.

Authors:  Jun-Neng Roan; Yu-Chuan Tsai; I-Wen Chen; Shih-Wei Chang; Chien-Chi Huang; Chen-Fuh Lam
Journal:  Heart Vessels       Date:  2011-05-17       Impact factor: 2.037

4.  Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons.

Authors:  Y H Zhang; M R Vasko; G D Nicol
Journal:  J Physiol       Date:  2006-06-01       Impact factor: 5.182

5.  Balance of S1P1 and S1P2 signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature.

Authors:  Jen-Fu Lee; Sharon Gordon; Rosendo Estrada; Lichun Wang; Deanna L Siow; Binks W Wattenberg; David Lominadze; Menq-Jer Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-14       Impact factor: 4.733

6.  Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine.

Authors:  Claudia Czyborra; Angela Bischoff; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-07       Impact factor: 3.000

Review 7.  Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertension.

Authors:  Xi-Qian Xing; Yan-Li Li; Yu-Xuan Zhang; Yi Xiao; Zhi-Dong Li; Li-Qiong Liu; Yu-Shan Zhou; Hong-Yan Zhang; Yan-Hong Liu; Li-Hui Zhang; Min Zhuang; Yan-Ping Chen; Sheng-Rong Ouyang; Xu-Wei Wu; Jiao Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

8.  Differential expression of sphingosine-1-phosphate receptors in abdominal aortic aneurysms.

Authors:  Z Qu; Bernice L Y Cheuk; Stephen W K Cheng
Journal:  Mediators Inflamm       Date:  2012-03-26       Impact factor: 4.711

9.  Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects.

Authors:  Salvatore Salomone; Christian Waeber
Journal:  Front Pharmacol       Date:  2011-02-22       Impact factor: 5.810

10.  Antinociceptive activity of the S1P-receptor agonist FTY720.

Authors:  Ovidiu Coste; Sandra Pierre; Claudiu Marian; Christian Brenneis; Carlo Angioni; Helmut Schmidt; Laura Popp; Gerd Geisslinger; Klaus Scholich
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.